Think

Search This Blog

Caregivers Are Too Slow to Reach for EpiPens, Study Finds

July 31, 2017

Get link
Facebook
Twitter
Pinterest
Email
Other Apps

By STEPH YIN via NYT Health

Get link
Facebook
Twitter
Pinterest
Email
Other Apps

Comments

A.L.S. Drug Relyvrio Will Be Taken Off the Market, Its Maker Says

Results of a large clinical trial found the treatment did not work any better than a placebo. Pam Belluck | NYTimes Health | Disclosure

Many U.S. virus cases go uncounted. Are there better ways to track the pandemic?

BY EMILY ANTHES | NYTimes Health | Disclosure

Hospitals Must Get Written Patient Consent for Pelvic Exams, H.H.S. Says

In a letter to teaching hospitals, the federal health agency said that institutions could lose Medicare funding if they didn’t comply. Emma Goldberg | NYTimes Health | Disclosure

A new drug slashes deaths among patients with severe Covid, the drug’s developer claims.

BY RONI CARYN RABIN | NYTimes Health | Disclosure

Sleep Apnea Reduced in People Who Took Weight-Loss Drug, Eli Lilly Reports

The company reported results of clinical trials involving Zepbound, an obesity drug in the same class as Novo Nordisk’s Wegovy. Gina Kolata | NYTimes Health | Disclosure

Powered by Blogger

Caregivers Are Too Slow to Reach for EpiPens, Study Finds

Comments

Post a Comment